Research Topics
| M TohenSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Olanzapine - relapse prevention following maniaSimon Dando
Eli Lilly and Company Limited, Basingstoke, UK
J Psychopharmacol 20:31-8. 2006..The safety and tolerability of the medicine is also examined, focusing on weight gain and metabolic issues...- Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trialMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 162:1281-90. 2005..The authors compared the efficacy of olanzapine and lithium in the prevention of mood episode relapse/recurrence... - Effect of comorbid anxiety on treatment response in bipolar depressionMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, United States
J Affect Disord 104:137-46. 2007..This secondary analysis from a randomized double-blind study of acute bipolar depression compared olanzapine monotherapy, olanzapine-fluoxetine combination (OFC) and placebo in patients with or without comorbid anxiety... - Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week studyMauricio Tohen
Lilly Research Laboratories, IN 46285, USA
Am J Psychiatry 160:1263-71. 2003..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex... - Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind studyMauricio Tohen
Lilly Research Laboratories, 450 South Madison Ave, Indianapolis, IN 46225, USA
J Clin Psychiatry 69:1776-89. 2008..To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria)... - Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapineMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 163:247-56. 2006..In a placebo-controlled, double-blind study, the authors investigated the efficacy and safety of olanzapine as monotherapy in relapse prevention in bipolar I disorder... - Olanzapine versus placebo in the treatment of adolescents with bipolar maniaMauricio Tohen
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
Am J Psychiatry 164:1547-56. 2007..The purpose of this study was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed episodes associated with bipolar disorder in adolescents... 
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodesMauricio Tohen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Br J Psychiatry 192:135-43. 2008..Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania...- Clinical trials in bipolar mania: implications in study design and drug developmentMauricio Tohen
Lilly Research Laboratories, Eli Lilly Corporate Center, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 65:252-3. 2008 - Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 60:1079-88. 2003.... - Olanzapine versus divalproex in the treatment of acute maniaMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 159:1011-7. 2002..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial... - Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorderMauricio Tohen
Lilly Corporate Center, Indianapolis, IN 46285, United States
J Affect Disord 116:43-50. 2009..In a population of patients with manic and mixed mood episodes, olanzapine has proven effective in maintaining response, as compared to placebo. Whether this is true for the subpopulation of patients with a mixed index episode is not known... - Olanzapine versus haloperidol in schizoaffective disorder, bipolar typeM Tohen
Lilly Research Laboratories, Indianapolis, IN, USA
J Affect Disord 67:133-40. 2001..The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol... - The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrenceMauricio Tohen
Lilly Research Laboratories, Brougher Building, 525 South Meridian, Indianapolis, IN 46225, USA
Am J Psychiatry 160:2099-107. 2003..Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset following first hospitalization for mania... - A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute maniaMauricio Tohen
Lilly Research Laboratories, Indianapolis, Ind 46225, USA
Arch Gen Psychiatry 60:1218-26. 2003..This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania... - Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Br J Psychiatry 184:337-45. 2004..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone... - Onset of action of antipsychotics in the treatment of maniaM Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Bipolar Disord 2:261-8. 2000..This article reviews the available published data from controlled, blinded studies regarding the latency of responses to antipsychotics in patients with acute mania... - Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study GroupM Tohen
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 USA
Arch Gen Psychiatry 57:841-9. 2000..We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania... - Influence of sub-syndromal symptoms after remission from manic or mixed episodesMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Br J Psychiatry 189:515-9. 2006..Sub-syndromal symptoms in bipolar disorder impair functioning and diminish quality of life... - Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapyMauricio Tohen
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 59:62-9. 2002..CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes... - Olanzapine versus haloperidol treatment in first-episode psychosisT M Sanger
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Am J Psychiatry 156:79-87. 1999..Hence, the authors examined patients with first-episode psychosis to determine the efficacy and safety of olanzapine and haloperidol treatment... - Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work statusL Shi
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Int Clin Psychopharmacol 17:227-37. 2002..In conclusion, compared to haloperidol, olanzapine treatment was comparably effective in the remission of bipolar mania and significantly improved HRQOL and work status in patients with bipolar I disorder... - A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar maniaK Meehan
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
J Clin Psychopharmacol 21:389-97. 2001..These findings suggest that intramuscular olanzapine is a safe and effective treatment for reducing acute agitation in patients with bipolar mania... - A meta-analysis of the use of typical antipsychotic agents in bipolar disorderM Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
J Affect Disord 65:85-93. 2001..Despite these concerns and the availability of mood stabilizing agents, the treatment of bipolar disorder with typical antipsychotic agents appears to be widespread... - Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trialBaojin Zhu
Lilly Research Laboratories, Indianapolis, IN, USA
Curr Med Res Opin 21:555-64. 2005.... - Functional impairment in patients with mania: baseline results of the EMBLEM studyI Goetz
European Health Outcomes, Lilly Research Centre, Windlesham, Surrey, UK
Bipolar Disord 9:45-52. 2007..We present an overview of the study design and patient characteristics at baseline while focusing on factors influencing work performance in the year prior to enrollment... - Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM studyD Novick
Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
Pharmacopsychiatry 42:145-52. 2009..The aim of this study was to compare the outcomes of olanzapine- and valproate-treated patients in an observational study of acute mania with the results of a randomised controlled trial (RCT) assessing the same treatments... - Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort studyA Montoya
Medical Department, Lilly Research Laboratories, Alcobendas, Spain
J Affect Disord 127:50-7. 2010..This study aimed to prospectively evaluate whether the presence of subsyndromal symptoms and level of functionality have long-term consequences in BD patients in syndromal remission... - Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM StudyA Montoya
Laboratorios Lilly, Spain
Actas Esp Psiquiatr 35:315-22. 2007..Although treatment for mania has been studied extensively in randomized clinical trials, there are few data that address how these patients are truly managed in clinical, functional, and economic terms in the psychiatric practice in Spain... - Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar maniaRobert W Baker
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
J Affect Disord 73:147-53. 2003..Presumably, bipolar patients would be at increased risk for this putative adverse event. Therefore, we evaluated the potential of olanzapine to exacerbate symptoms of mania compared to placebo during treatment of bipolar mania... - Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute maniaLizheng Shi
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Curr Med Res Opin 20:1371-6. 2004.... - Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depressionSanjay Dube
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Bipolar Disord 9:618-27. 2007..The current analysis investigated the onset of antidepressant effect of olanzapine/fluoxetine combination... - Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trialsPatrizia A Cavazzoni
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychiatry 67:107-13. 2006..The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder... - Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine toolsJamie Karagianis
Eli Lilly Canada Inc, Toronto, Ontario, Canada
Curr Med Res Opin 23:2551-7. 2007.... - Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger
Lilly Research Laboratories, Indianapolis, IN 46285, USA
J Affect Disord 73:155-61. 2003..CONCLUSIONS: These results indicate that olanzapine was effective in reducing symptoms of mania and well tolerated in patients with bipolar I disorder with a rapid-cycling course... - Clinical relevance of depressive symptom improvement in bipolar I depressed patientsDoug Williamson
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
J Affect Disord 92:261-6. 2006..Gaps remain between rating scale changes obtained in a clinical trial and what those results mean in clinical practice... - Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproexJohn P Houston
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46221, USA
J Clin Psychiatry 67:1246-52. 2006..To identify symptoms associated with suicidality in bipolar I disorder patients, and to assess suicide risk during treatment with olan-zapine in combination with lithium or divalproex... - Acute dysphoric mania: treatment response to olanzapine versus placeboRobert W Baker
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
J Clin Psychopharmacol 23:132-7. 2003..Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms... - Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trialLudmila Kryzhanovskaya
Eli Lilly and Company
J Am Acad Child Adolesc Psychiatry 48:60-70. 2009..To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia... - Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trialLizheng Shi
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Clin Ther 26:125-34. 2004..Improving patients' health-related quality of life (HRQOL) could be a treatment goal for bipolar depression... - Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depressionEileen Brown
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Int J Neuropsychopharmacol 12:773-82. 2009..There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia... - Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practiceDiego Novick
Lilly Research Centre, Windlesham, Surrey, UK
Int Clin Psychopharmacol 25:257-63. 2010..Limitations include differences in study design, patient population, and length of follow-up... - Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acidMadhav A Namjoshi
Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Bldg 75 05, DC1758, Indianapolis, IN 46285, USA
J Affect Disord 81:223-9. 2004..The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder... - Work impairment in bipolar disorder patients--results from a two-year observational study (EMBLEM)C Reed
Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, Windlesham GU20 6PH, UK
Eur Psychiatry 25:338-44. 2010..To explore factors associated with work impairment at 2 years following an acute episode... - Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled studyJohn P Houston
Lilly USA, LLC, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychiatry 70:1540-7. 2009.... - Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric maniaRobert W Baker
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
Br J Psychiatry 185:472-8. 2004..Few controlled studies examine the treatment of depressive features in mania... - Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysisInge van Rossum
Medical Department, Eli Lilly Nederland, Houten, The Netherlands
J Nerv Ment Dis 197:35-40. 2009..An independent impact of cannabis use on psychopathologic outcomes in patients with bipolar disorder was apparent, whereas the impact on social outcomes was modest... - Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyHaya Ascher-Svanum
U S Outcomes Research, Eli Lilly and Co, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
J Clin Psychiatry 69:1580-8. 2008..The objective of this study was to compare the 3-year course of schizophrenia between persons with tardive dyskinesia (TD) and persons without TD on multiple outcome measures... - A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depressionEileen B Brown
Lilly Research Laboratories, Indianapolis, IN, USA
J Clin Psychiatry 67:1025-33. 2006..Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine... - Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelinesP Z Lim
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Bipolar Disord 3:165-73. 2001..CONCLUSIONS: Results suggest that a substantial proportion of patients with bipolar I disorder are discharged from hospitals on medications not generally recommended by current practice guidelines... - The Bipolar Depression Rating Scale (BDRS): its development, validation and utilityMichael Berk
Barwon Health and The Geelong Clinic, Geelong Department of Clinical and Biomedical Sciences, University of Melbourne and ORYGEN Research Centre, Melbourne, Victoria, Australia
Bipolar Disord 9:571-9. 2007..Both clinically and in research there is a growing need for a new observer-rated scale that is specifically designed to assess bipolar depression... - Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factorsHari Mandir Kaur Khalsa
Department of Psychiatry, Harvard Medical School, Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA 02478 9106, USA
J Affect Disord 106:179-84. 2008..Risks of life-threatening behaviors are high among bipolar disorder (BPD) patients, but early rates and associated risk factors for suicides and accidents remain ill-defined... - Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar maniaK N Roy Chengappa
Western Psychiatric Institute and Clinic, Mayview State Hospital, University of Pittsburgh Medical Center, PA 15213 2593, USA
Bipolar Disord 5:1-5. 2003.... - Pharmacotherapy patterns in the treatment of bipolar disorderPatricia Russo
The MEDSTAT Group, Washington, DC 20008, USA
Bipolar Disord 4:366-77. 2002..To assess medication use patterns of patients with bipolar disorder, and, through multivariate analysis, to elucidate the role of selected demographic and clinical factors on medication choice and use patterns... - Going up in smoke: tobacco smoking is associated with worse treatment outcomes in maniaMichael Berk
University of Melbourne, Victoria, Australia
J Affect Disord 110:126-34. 2008..This study aimed to compare the treatment responses between smokers and non-smokers in bipolar mania clinical trials... - The empirical redefinition of the psychometric criteria for remission in bipolar disorderMichael Berk
Barwon Health and The Geelong Clinic, Geelong, Victoria, Australia
J Affect Disord 106:153-8. 2008.... - Stability and treatment outcome of distinct classes of maniaInge van Rossum
Medical Department, Eli Lilly Nederland, Grootslag 1 5, Houten, The Netherlands
Eur Psychiatry 23:360-7. 2008..Differential treatment course and outcome after 12 weeks of treatment were examined for three distinct classes of patients with acute mania in bipolar disorder... - Sex differences in clinical response to olanzapine compared with haloperidolJill M Goldstein
Harvard Institute of Psychiatric Epidemiology and Genetics, Department of Psychiatry, Harvard Medical School at Massachusetts Mental Health Center, MMHC, Boston, MA 02115, USA
Psychiatry Res 110:27-37. 2002..Finally, premenopausal women had a significantly better treatment response than postmenopausal women, regardless of treatment and chronicity... - Weight gain during treatment of bipolar I patients with olanzapineJohn Hennen
Department of Psychiatry, Harvard Medical School, Boston, MA, USA
J Clin Psychiatry 65:1679-87. 2004..Body weight increase during long-term treatment with olanzapine in schizophrenia patients is well documented, but weight gain and its association with other medical measures are less well evaluated in bipolar disorder patients... - Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational studyEduard Vieta
Bipolar Disorders Program, Hospital Clinic, University of Barcelona IDIBAPS, Barcelona, Spain
J Affect Disord 106:63-72. 2008.... - Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trialGu Niufan
Shanghai Mental Health Center, Shanghai, People s Republic of China
J Affect Disord 105:101-8. 2008..This multicenter, double-blind, randomized, controlled study conducted in China examined the efficacy and safety of olanzapine versus lithium in the treatment of patients with bipolar manic/mixed episodes... - Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patientsCarlos A Zarate
Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
Am J Psychiatry 161:169-71. 2004..The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode... - Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episodeStephen M Strakowski
Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
Schizophr Res 78:161-9. 2005..This improvement is particularly relevant early in the course of schizophrenia... - Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depressionPaul E Keck
Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
J Clin Psychiatry 66:611-6. 2005..These subanalyses compare treatment-emergent mania rates in bipolar I depressed patients treated with olanzapine, placebo, or olanzapine/fluoxetine combination... - Substance abuse in first-episode bipolar I disorder: indications for early interventionChristopher Baethge
Department of Psychiatry, Harvard Medical School, Boston, MA, USA
Am J Psychiatry 162:1008-10. 2005..This study clarified the early characteristics of substance use disorders in patients with first-episode bipolar I disorder... - Antipsychotic drug effects on brain morphology in first-episode psychosisJeffrey A Lieberman
Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Arch Gen Psychiatry 62:361-70. 2005..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia... - Recovery and functional outcomes following olanzapine treatment for bipolar I maniaK N Roy Chengappa
Western Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213 2593, USA
Bipolar Disord 7:68-76. 2005..Typical experimental categorizations of treatment responses in bipolar disorder (BPD) patients may have limited relationship to clinical recovery or functional status, and there is inadequate research on such clinically important outcomes... - Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled dataEduard Vieta
Bipolar Disorders Program, Department of Psychiatry, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
J Clin Psychiatry 65:1420-8. 2004..We report on the first controlled study comparing acute and continuous clinical outcomes in RC and non-RC manic patients treated with olanzapine... - An excitement subscale of the Positive and Negative Syndrome ScaleJean Pierre Lindenmayer
Department of Psychiatry, New York University School of Medicine, and Manhattan Psychiatric Center, Wards Island Complex, New York, NY, USA
Schizophr Res 68:331-7. 2004.... - Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disordersDiana Perkins
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, 27599 7160
Br J Psychiatry 185:18-24. 2004..Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia... - Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
Biol Psychiatry 59:97-105. 2006..Neurocognitive deficits are severe in first-episode psychosis... - Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week dataTrisha Suppes
University of Texas Southwestern Medical Center, Dallas, TX 75390 9121, United States
J Affect Disord 89:69-77. 2005..Rapid cycling in bipolar disorder has been associated with greater morbidity. We examine whether rapid cycling affects treatment response to olanzapine or divalproex in acute mania... - Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodesTerence A Ketter
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
J Clin Psychiatry 67:95-101. 2006..Thus, olanzapine maintenance therapy may be particularly effective early in the course of bipolar illness... - Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic featuresMelissa P DelBello
The Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
J Child Adolesc Psychopharmacol 13:173-85. 2003.... - Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidolJorge M Tamayo
Department of Psychiatry, CES University, Medellin, Colombia
J Clin Psychopharmacol 27:126-34. 2007..The pattern of adverse events differed between treatment groups. Prospective clinical trials in Latin American bipolar populations are justified... - Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidolJeffrey A Lieberman
Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
Am J Psychiatry 160:1396-404. 2003..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial... - Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trialRoy H Perlis
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 67:1747-53. 2006..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes... - Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodromeScott W Woods
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
Biol Psychiatry 54:453-64. 2003..Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment... - Insight in first-episode psychosisJoseph P McEvoy
John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
Psychol Med 36:1385-93. 2006.... - Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan
Department of Psychiatry, Yale University School of Medicine, 301 Cedar St, New Haven, CT 06519, USA
Am J Psychiatry 163:790-9. 2006..This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia... - Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeDiana O Perkins
Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
Schizophr Res 83:53-63. 2006.... - Olanzapine versus placebo in acute mania: treatment responses in subgroupsRoss J Baldessarini
International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
J Clin Psychopharmacol 23:370-6. 2003..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania... - Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidolRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
Am J Psychiatry 161:985-95. 2004..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis...